Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes

NCT02372955 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG: dapagliflozin
DRUG: glimpiride

Sponsor

Gulf Regional Research & Educational Services, LLC